Search

everythinglearnresearchcommunity

for

Search:↓

Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.

Targeting ornithine decarboxylase can help prevent skin cancer.

Vemurafenib can cause scalp issues but can be managed without changing the dose.

ALRN-6924 may prevent hair loss caused by chemotherapy.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Suppressing ODC activity reduces tumor growth in hair follicles.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

A man developed alopecia areata after starting cancer treatment with vandetanib.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

High MUC-18/MCAM levels in blood indicate a worse outlook for melanoma patients.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

The document concludes that the development of certain tumors is influenced by genetic background and that a specific gene modification can lead to tumor regression and reduced growth.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

EGFR-targeting cancer drugs can cause skin rashes and other side effects.

The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.

The microenvironment affects the behavior and survival of melanocytes with the GNAQ oncogene in melanoma.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

The study found that analyzing certain cell signaling pathways is not a reliable method to tell apart two types of skin tumors.